Compare · BDX vs HSAQ
BDX vs HSAQ
Side-by-side comparison of Becton Dickinson and Company (BDX) and Health Sciences Acquisitions Corporation 2 (HSAQ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and HSAQ operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $72.89B, about 361.5x HSAQ ($201.6M).
- BDX has hit the wire 9 times in the past 4 weeks while HSAQ has been quiet.
- BDX has more recent analyst coverage (25 ratings vs 0 for HSAQ).
- Company
- Becton Dickinson and Company
- Health Sciences Acquisitions Corporation 2
- Price
- $152.11-1.77%
- $13.31+25.98%
- Market cap
- $72.89B
- $201.6M
- 1M return
- -3.89%
- -
- 1Y return
- -25.68%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 9
- 0
- Recent ratings
- 25
- 0
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Health Sciences Acquisitions Corporation 2
Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.
Latest BDX
- BD Earns Industry Top Honors for Transparency, Resiliency and Partnership
- Goldman resumed coverage on Becton Dickinson with a new price target
- Becton Dickinson and Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- BD to Announce Financial Results for its Second Quarter of Fiscal 2026
- Rick Byrd to Retire from BD
- For Women Managing Nighttime Incontinence, Better Sleep and Comfort Start with BD® PureWick® Urine Collection System
- BD Delivers Next‑Generation TIPS Innovation to Advance Portal Hypertension Care Across the European Union
- When Every Beat Matters, BD Helps Clinicians Eliminate Blind Spots with Continuous, Noninvasive Blood Pressure Insight
- SEC Form 4 filed by Neal Shana Carol
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest HSAQ
- SEC Form 5 filed by Medtronic Plc
- SEC Form SC 13G/A filed by Health Sciences Acquisitions Corporation 2 (Amendment)
- SEC Form SC 13G/A filed by Health Sciences Acquisitions Corporation 2 (Amendment)
- SEC Form SC 13G filed by Health Sciences Acquisitions Corporation 2
- Health Sciences Acquisitions Corporation 2 filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Health Sciences Acquisitions Corporation 2 filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by Health Sciences Acquisitions Corporation 2
- Health Sciences Acquisitions Corporation 2 filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form S-1 filed by Health Sciences Acquisitions Corporation 2
- New insider Papandreou George claimed ownership of 20,000 shares (SEC Form 3)